>100 million patients worldwide, including over 20 million in Europe
>90 different autoimmune diseases, e.g. juvenile diabetes, rheumatoïd arthritis, IBD, multiple sclerosis
the incidence of IBD has risen by 60% over the last 8 years
> €120 billion global annual cost of care
CEO and co Founder
A seasoned biopharmaceutical executive and serial entrepreneur, Dr, Baum has participated in the founding of over 30 start ups located in Europe, the US and Israel. To-date, six have had successful exits. Dr. Baum teamed up with Dr. Cohen’s in founding Alma Biotherapeutics in order to apply new knowledge of the mechanisms underlying autoimmune disease to the development of therapeutic interventions for these chronic conditions.
Inventor, Chief Scientific Advisor and co Founder
Decades of research conducted by Dr. Cohen are the foundation for Alma’s Biotherapeutics drug discovery and development platform. Dr. Cohen is a world leading research immunologist who has received the Robert Koch Prize and the AESKU Prize for his Life Contribution to Autoimmunity Research. Dr. Cohen remains a Professor Emeritus of Immunology, Weizmann Institute of Science.
Director of Preclinical Development and Regulatory Affairs
Dr. Ravel brings 30 years’ experience as executive who has ushered drugs from concept to to the clinic for bio-pharmaceutical companies including Servier, Genset/MerckSerono, and Diatos.
Non Executive Director
“Immunity is a balancing act. Our approach attempts to tilt the balance away from the harmful inflammation associated with autoimmune diseases and toward healing.” World Leading Research Immunologist, Irun Cohen, Professor Emeritus of Immunology